ENTBF
Price
$0.09
Change
-$0.00 (-0.00%)
Updated
Apr 1 closing price
Capitalization
1.02M
OVID
Price
$0.28
Change
-$0.02 (-6.67%)
Updated
Apr 4 closing price
Capitalization
19.92M
32 days until earnings call
Ad is loading...

ENTBF vs OVID

Header iconENTBF vs OVID Comparison
Open Charts ENTBF vs OVIDBanner chart's image
ENTHEON BIOMEDICAL
Price$0.09
Change-$0.00 (-0.00%)
Volume$261
Capitalization1.02M
Ovid Therapeutics
Price$0.28
Change-$0.02 (-6.67%)
Volume$363.87K
Capitalization19.92M
ENTBF vs OVID Comparison Chart
Loading...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTBF vs. OVID commentary
Apr 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTBF is a Hold and OVID is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 06, 2025
Stock price -- (ENTBF: $0.09 vs. OVID: $0.28)
Brand notoriety: ENTBF and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTBF: 14% vs. OVID: 85%
Market capitalization -- ENTBF: $1.02M vs. OVID: $19.92M
ENTBF [@Biotechnology] is valued at $1.02M. OVID’s [@Biotechnology] market capitalization is $19.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $283.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTBF’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 1 green FA rating(s).

  • ENTBF’s FA Score: 0 green, 5 red.
  • OVID’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTBF is a better buy in the long-term than OVID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OVID’s TA Score shows that 3 TA indicator(s) are bullish.

  • OVID’s TA Score: 3 bullish, 3 bearish.

Price Growth

ENTBF (@Biotechnology) experienced а +3.79% price change this week, while OVID (@Biotechnology) price change was -19.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.00%. For the same industry, the average monthly price growth was -16.69%, and the average quarterly price growth was -18.23%.

Reported Earning Dates

OVID is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-11.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OVID($19.9M) has a higher market cap than ENTBF($1.02M). ENTBF YTD gains are higher at: -35.280 vs. OVID (-69.840). ENTBF has higher annual earnings (EBITDA): -323.3K vs. OVID (-61.27M). OVID has more cash in the bank: 53.1M vs. ENTBF (229K). OVID has higher revenues than ENTBF: OVID (566K) vs ENTBF (0).
ENTBFOVIDENTBF / OVID
Capitalization1.02M19.9M5%
EBITDA-323.3K-61.27M1%
Gain YTD-35.280-69.84051%
P/E RatioN/AN/A-
Revenue0566K-
Total Cash229K53.1M0%
Total DebtN/A14.8M-
FUNDAMENTALS RATINGS
OVID: Fundamental Ratings
OVID
OUTLOOK RATING
1..100
52
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
90
SEASONALITY SCORE
1..100
17

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
OVID
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
N/A
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 26 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STXS1.66-0.01
-0.60%
Stereotaxis
MAC14.52-1.08
-6.92%
Macerich Company (The)
FUBO2.80-0.22
-7.28%
fuboTV
BRO115.01-9.42
-7.57%
Brown & Brown
CNVS2.62-0.29
-9.97%
Cineverse Corp

ENTBF and

Correlation & Price change

A.I.dvisor tells us that ENTBF and AVTE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTBF and AVTE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTBF
1D Price
Change %
ENTBF100%
N/A
AVTE - ENTBF
32%
Poorly correlated
-0.80%
OVID - ENTBF
23%
Poorly correlated
-6.57%
IMRN - ENTBF
22%
Poorly correlated
-1.11%
HSTC - ENTBF
22%
Poorly correlated
N/A
ATNF - ENTBF
21%
Poorly correlated
-1.59%
More

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with AVTE. These tickers have moved in lockstep 89% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then AVTE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-6.57%
AVTE - OVID
89%
Closely correlated
-0.80%
SYRE - OVID
45%
Loosely correlated
-8.58%
NAUT - OVID
36%
Loosely correlated
-7.27%
TVTX - OVID
36%
Loosely correlated
-9.48%
KPRX - OVID
36%
Loosely correlated
-7.31%
More